HOME >> MEDICINE >> NEWS
Biomolecule studied for medical uses

DURHAM, N.C. -- Duke University Chemistry Department researchers are creating unique polymers out of naturally occurring building blocks that don't provoke immune reactions and in some cases also biodegrade in the body. The tree-like, globular-shaped substances are being evaluated for a variety of medical uses.

Called biodendrimers, these structures are prepared by systematically reacting acids with alcohols to form what chemists call "esters." The results are branching molecular chains with finger-like ends that can form sticky and tenacious links with other substances.

These characteristics make them "ideal candidates for medical and tissue engineering applications," said Mark Grinstaff, the assistant chemistry professor who heads the Duke team. One potential application, which Duke Medical Center eye researchers are beginning to test, is a glue that could "close a wound and then be dissolved as new tissue grows in to repair the wound site," he added in an interview.

"It could really potentially change the way we do corneal surgery," added Dr. Terry Kim, associate director of the Corneal and Refractive Surgery Service at the Duke Eye Center and a medical center assistant professor of ophthalmology.

Another possibility, which biomedical researchers at Duke's Pratt School of Engineering have also started investigating, would be using such biodendrimers as scaffolding to help induce cells to repair damaged human joints.

"Biodendrimers appear to interact with cells in completely novel manners," said Lori Setton, assistant professor and Harold L. Yoh Faculty Scholar in the Pratt School's Department of Biomedical Engineering. Because of its promise, Grinstaff's research just received $250,000 in funding from the Johnson & Johnson Focused Giving program, established to stimulate exploration in medical science. Other funding sources include the Pew, Sloan and Dreyfus foundations.

In a spring 2001 issue of the Journal of the Americ
'"/>

Contact: Monte Basgall
monte.basgall@duke.edu
919-681-8057
Duke University
30-Aug-2001


Page: 1 2 3 4

Related medicine news :

1. Technology that could double the effectiveness of cancer drugs studied at Yale
2. New global trials help to make FOSRENOL(R) the most extensively studied modern phosphate binder
3. Mind-body connection in placebo surgery trial studied by University of Denver researcher
4. Possible brain cancer-air pollution link to be studied
5. Investigational mesh jackets studied as an experimental therapy for heart failure
6. Venlafaxine XR, first SNRI studied for social anxiety disorder
7. New pathway for treating hypertension-related kidney failure studied
8. Intensification therapy studied in head and neck cancer
9. Chronic disease: the overlooked & understudied epidemic
10. Advertising by academic medical centers may risk eroding public trust, says study
11. NIH state-of-the-science panel calls for demedicalization of menopause

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Biomolecule studied for medical uses

(Date:7/30/2014)... teaching hospital in Ireland has shown than many of them ... minimise the risk of entrapment. The report, published online in ... need for careful selection of patients for whom bedrails are ... and maintenance of hospital bed systems. , Bedrails are commonly ... However, although the risk for any individual is extremely low, ...
(Date:7/30/2014)... July 30, 2014 Victory Medical ... proud to announce the launch of a pediatric unit ... general surgery. The doctors working in the pediatrics departments ... infants, children, and adolescents. Dr. Timothy Cole, Dr. Dale ... McDuffie, Dr. Neelesh Mehendale, and Dr. Nicholas Peiffer lead ...
(Date:7/30/2014)... 30, 2014 Dialogic Inc. ... announced that DollarPhone, the largest privately owned calling ... Dialogic® ControlSwitchâ„¢ softswitch to offer enhanced ... portability (LNP) to both its wholesale and prepaid ... is able to power DollarPhone’s network infrastructure, allowing ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... -- ,Middle-aged adults with a history of alcohol abuse ... develop severe memory problems later in life, according to ... findings could help doctors identify those at risk for ... drinking. "We already know there is an association ... -- that understanding is based on asking older people ...
Breaking Medicine News(10 mins):Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2
(Date:7/29/2014)... 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... two healthcare conferences during the third quarter, the 2014 ... Global Healthcare 2014 Conference.  Alexza,s corporate presentation will be ... on each event are below: , 2014 ... in Boston , MA.  The format ...
(Date:7/29/2014)... Inc. (NYSE: CVD ) today reported results ... revenue was $639 million, representing 8.0% growth from the ... company reported earnings of $0.29 per diluted share in ... per diluted share of $0.95, up 21.5% over the ... impairment charges totaling $52.6 million, or $0.61 per share, ...
(Date:7/29/2014)... New technology in the form of a ... see and assess brain tissue more clearly while treating ... who released their findings today at the Society of ... Colorado Springs, CO. ... a specialty that facilitates stroke treatment by navigating a ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
Cached News: